NCT04305834招募中2 期
A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination With Endocrine Therapy in Patients Age 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition
City of Hope Medical Center9 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2020年3月25日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 43
- 试验地点
- 9
- 主要终点
- Incidence of grade 3 or higher toxicities
研究概览
简要总结
This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.
详细描述
PRIMARY OBJECTIVE:
I. To estimate the incidence of grade 3 or higher toxicities attributed to abemaciclib monotherapy in adults aged 70 or older with hormone receptor positive metastatic breast cancer.
SECONDARY OBJECTIVES:
I. To describe the full toxicity profile including all grade 2 and higher adverse events, and patient-reported adverse events (AEs) using Patients Reported Outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE) measures.
II. To describe rates of dose reductions, dose holds, treatment discontinuations due to factors other than progression, and hospitalizations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented informed consent of the participant
- •Age >= 70 years
- •Life expectancy > 6 months
- •Ability to read and understand English or Spanish
- •Measurable or non-measurable disease
- •Histologically or cytologically confirmed diagnosis of:
- •Estrogen-receptor positive and/or progesterone receptor positive breast cancer determined by immunohistochemistry (IHC) methods according to the local institution standard protocol
- •HER2-negative breast cancer defined as negative if the IHC status is 0 or 1+, or if IHC is 2+ and in situ hybridization assay is negative per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines
- •Radiographically confirmed metastatic breast cancer
- •Progressed on prior endocrine therapy or palbociclib or ribociclib or chemotherapy
- •Patients who received chemotherapy recovered from the acute side effects to prior cancer therapy (except alopecia or residual grade 2 peripheral neuropathy) to =< grade 1 or baseline. A washout period of at least 21 days is required between last chemotherapy dose and randomization (provided the patient did not receive radiotherapy)
- •Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomization
- •Absence of central nervous system (CNS) involvement unless they meet ONE of the following criteria:
- •Untreated brain metastases (e.g., lesions < 1 cm) not needing immediate local therapy
- •Previously treated brain metastases not needing immediate local therapy
- •At least 4 weeks from the last date of prior therapy completion (including radiation and/or surgery) to starting the study treatment
- •Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
- •Absence of interstitial lung disease/pneumonitis
- •Absolute neutrophil count (ANC) >= 1.5 X 10^9/L
- •Platelets >= 100 x 10^9/L
- •Hemoglobin >= 8 g/dL
- •(Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion)
- •In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x upper limit of normal (ULN)
- •If the patient has liver metastases, ALT and AST < 5 x ULN
- •In patients without Gilbert's syndrome, total bilirubin =< 1.5 x ULN; In patients with Gilbert's syndrome, total bilirubin =< 2.0 x ULN or direct bilirubin within normal limits (WLN)
- •Creatinine clearance of >= 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula
排除标准
- •Major surgery within 14 days prior to receiving study drug or has not recovered from major side effect
- •Patient is currently receiving any of the prohibited medications detailed below and cannot be discontinued 7 days prior to starting study drug
- •Other investigational therapy should be given to participants
- •Anticancer agents other than the study medications administered as part of this study protocol should be given to participants. If such agents are required for a participant then the participant must first be withdrawn from the study
- •Co-medication that may interfere with study results; e.g. immune-suppressive agents other than corticosteroids, such as systemic cyclosporine and tacrolimus are prohibited during the treatment phase of the study, unless discussed with principal investigator felt to be of low clinical risk to the participant
- •Use of herbal medications may have unknown interactions with the metabolism of the study agents, and therefore are prohibited from use during the treatment phase of the trial
- •Known hypersensitivity to any of the excipients of abemaciclib
- •Active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C (for example, hepatitis B surface antigen positive). Screening is not required for enrollment
- •Impairment of gastrointestinal (GI) function or GI disease that in the investigator's opinion may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
- •History of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
- •Patient has any other concurrent severe or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis)
- •Inability to swallow oral medications
- •Serious or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance < 30 ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea)
- •History of non-compliance to medical regimen
- •Patients with a prior malignancy diagnosed within 2 years and with evidence of disease (except adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer
研究组 & 干预措施
Treatment (abemaciclib)
Experimental
Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Questionnaire Administration (Other)
Treatment (abemaciclib)
Experimental
Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Abemaciclib (Drug)
结局指标
主要结局
Incidence of grade 3 or higher toxicities
时间窗: Up to 30 days post treatment
Adverse events will be characterized using the descriptions and grading scales found in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v). 5.0.
次要结局
- Incidence of toxicities(Up to 30 days post treatment)
- Time to end of treatment(Up to end of treatment)
- Was It Worth It (WIWI) response(Up to end of treatment)
- Incidence of toxicities(Up to cycle 6)
- Dose reductions(Up to cycle 6)
- Dose holds(Up to 30 days post treatment)
- Treatment discontinuations due to factors other than progression(Up to 30 days post treatment)
- Hospitalizations(Up to 2 years post treatment)
- Progression free survival(Up to 2 years post treatment)
- Adherence to abemaciclib(Up to end of treatment)
- Average plasma steady-state abemaciclib C-trough concentrations(Up to 2 years post treatment)
- Pharmacokinetic (PK) parameter of plasma trough concentration(Up to 2 years post treatment)
- Overall survival(Up to 2 years post treatment)
- Overall treatment utility (OTU) response(Up to end of treatment)
- Geriatric assessment scores(Up to 2 years post treatment)
- Incidence of toxicities attributable to agent(Up to 2 years post treatment)
研究者
研究点 (9)
Loading locations...
相似试验
进行中（未招募）
2 期
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain TumorsBrain TumorNCT03220646Memorial Sloan Kettering Cancer Center64
终止
2 期
Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate CancerProstate CancerNCT04298983University of Alabama at Birmingham9
已完成
2 期
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung CancerNon-Small Cell Lung Cancer Stage IVNCT02450539Eli Lilly and Company159
招募中
1 期
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian CancerRecurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaNCT04633239National Cancer Institute (NCI)42
已完成
2 期
Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative ColitisUlcerative ColitisNCT00572585Novartis Pharmaceuticals60